等待開盤 01-29 09:30:00 美东时间
-0.180
-4.30%
<p>Apyx Medical Corporation reported strong fourth-quarter and full-year 2025 revenue growth. Surgical Aesthetics revenue increased 38% year-over-year in Q4, driven by a 51% jump in the U.S. following the launch of AYON. Total Q4 revenue was $19.0-$19.2 million, up 34% from the prior year. Full-year revenue reached $52.7-$52.9 million, an 10% increase, with Surgical Aesthetics up 17%. The company attributes its success to the adoption of AYON and...
01-12 13:00
今日重点评级关注:富国银行:维持Milestone Pharmaceuticals"超配"评级,目标价从4美元升至8美元;富国银行:维持Kyverna Therapeutics"超配"评级,目标价从31美元升至33美元
2025-12-17 10:46
Roth Capital analyst Kyle Bauser initiates coverage on Apyx Medical (NASDAQ:APYX) with a Buy rating and announces Price Target of $6.
2025-12-16 23:19
Wall Street research looks to be shifting from endorsing the classic AI trade to AI adopters. Instead of the chipmakers and hyperscalers in the megacap sectors (XLK) (XLC) (XLY) that are making AI pos...
2025-12-09 17:28
Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the
2025-12-03 21:05
An announcement from Apyx Medical ( ($APYX) ) is now available. On November 18,...
2025-11-20 06:08
Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it
2025-11-18 05:07
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从12美元升至15美元;Canaccord Genuity:维持Viking Therapeutics"买入"评级,目标价从106美元升至107美元
2025-11-13 09:58
Earnings Call Insights: Apyx Medical Corporation (APYX) Q3 2025 Management View Charles Goodwin, President and CEO, announced the official rebranding of the Advanced Energy segment to Surgical Aesthet...
2025-11-07 03:36
Apyx Medical shares are trading higher after the company reported better-than-e...
2025-11-06 23:37